相关实验视频

Updated: Feb 27, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

一个罕见的病例报告复发/耐药的原发性皮肤扩散性大B细胞淋巴瘤,腿类型,用Epcoritamab治疗:获得的结果和经验教训

Alessandro Cafaro¹, Francesco Malaspina², Pietro Rossi²

¹Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

Frontiers in oncology

|February 26, 2026

概括

在患有复发性/耐药性初级皮肤扩散性大B细胞淋巴瘤,腿类型的患者中,epcoritamab显示出暂时的反应. 由于CD20表达损失,早期复发发生了CD20向治疗中的抗性机制.

科学领域:

血液学血液学血液学
在瘤学瘤学.
皮肤病学皮肤病学

背景情况:

初级皮肤扩散大B细胞淋巴瘤,腿类型 (PCDLBCL-LT) 是具有不良预后的侵略性.
对于复发性或耐火性PCDLBCL-LT存在有限的治疗选择.
标准治疗包括基于Rituximab的化疗免疫疗法 (R-CHOP).

研究的目的:

报告第一个复发/耐药PCDLBCL-LT病例,该病例用双特异性CD20向抗体治疗.
调查治疗反应和耐药性机制.

主要方法:

一个72岁的男性患有复发性/耐药性PCDLBCL-LT的病例报告.
以epcoritamab作为第四线疗法治疗之前的多种疗法后的治疗.
监测临床反应和CD20表达.

主要成果:

患者获得了Epcoritamab的初始临床反应,包括皮肤病变的回归.
早期复发发生在治疗开始后不久.
复发与CD20表达的丧失一致,这表明了耐药性.

结论:

在复发/耐药PCDLBCL-LT中,epcoritamab可能会诱导反应.
CD20表达的丧失是对CD20导向疗法的潜在抵抗机制,可能因之前的Rituximab暴露而加剧.
这一案例凸显了对PCDLBCL-LT.双特异抗体有效性和耐药性的进一步调查的需要.

关键词:

CD20 CD20 是一个CD20 CD20 是一个CD20.埃普科里他马布 (Epcoritamab) 的使用方法腿类型腿类型腿类型初级皮肤扩散大B细胞淋巴瘤皮肤病变皮肤病变

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...